Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RxSight (RXST) Other Non-Current Liabilities (2020 - 2025)

RxSight filings provide 5 years of Other Non-Current Liabilities readings, the most recent being $3.2 million for Q4 2025.

  • On a quarterly basis, Other Non-Current Liabilities rose 88.24% to $3.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $3.2 million, a 88.24% increase, with the full-year FY2025 number at $3.2 million, up 88.24% from a year prior.
  • Other Non-Current Liabilities hit $3.2 million in Q4 2025 for RxSight, up from $1.7 million in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $3.2 million in Q4 2025 to a low of $74000.0 in Q4 2023.
  • Median Other Non-Current Liabilities over the past 4 years was $888000.0 (2023), compared with a mean of $1.3 million.
  • Biggest five-year swings in Other Non-Current Liabilities: surged 2197.3% in 2024 and later soared 88.24% in 2025.
  • RxSight's Other Non-Current Liabilities stood at $2.6 million in 2021, then crashed by 97.17% to $74000.0 in 2023, then surged by 2197.3% to $1.7 million in 2024, then soared by 88.24% to $3.2 million in 2025.
  • The last three reported values for Other Non-Current Liabilities were $3.2 million (Q4 2025), $1.7 million (Q4 2024), and $74000.0 (Q4 2023) per Business Quant data.